Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1985;19(Suppl 2):177S–184S. doi: 10.1111/j.1365-2125.1985.tb02759.x

A multiple-dose comparative study of the pharmacodynamic and pharmacokinetic behaviour of polymer-matrix and Oros dosage forms of oxprenolol in healthy volunteers

K L Woods, D B Jack, M J Kendall, Alison Halsey, M Louise O'Donnell, S J Warrington, V A John
PMCID: PMC1463772  PMID: 4005120

Abstract

1 A new osmotic drug delivery system (Oros) has been evaluated in multiple-dose studies in young healthy volunteers as a sustained-release vehicle for once-daily administration of oxprenolol. Two Oros systems were examined in two separate studies, one containing 170 mg oxprenolol succinate with an initial zero-order release rate of 10 mg/h, and the other containing 260 mg oxprenolol succinate with an initial release rate of 16 mg/h. These were compared respectively with conventional oxprenolol hydrochloride (Trasicor®) 80 mg twice daily and polymer-matrix oxprenolol hydrochloride (Slow Trasicor®) 160 mg once daily.

2 Variations in mean plasma levels and β-adrenoceptor blockade (measured by inhibition of exercise tachycardia) were considerably reduced on the 10/170 Oros once-daily compared with the Trasicor 80 mg twice-daily regimen. With both formulations there was no significant change in mean plasma concentrations or areas under the curve after 8 days' treatment, and similar pre-dose plasma concentrations were obtained. There was significant inhibition of exercise tachycardia throughout 24 h after the 10/170 Oros on the eighth day.

3 The 16/260 Oros system gave smoother pharmacokinetic and pharmacodynamic profiles, and on repeated dosing a higher mean pre-dose plasma oxprenolol concentration than Slow Trasicor. Drug availability was similar for the two dose forms, suggesting an acceptable level of absorption of oxprenolol from most of the gastrointestinal tract. On the eighth day exercise heart rate was significantly reduced throughout 24 h with 16/260 oxprenolol Oros, but only between 1 and 15 h with Slow Trasicor.

Keywords: oxprenolol, Oros dosage form, pharmacokinetics, pharmacodynamics

Full text

PDF
177S

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Davidson R. G. Detection of carriers of inherited disorders. Birth Defects Orig Artic Ser. 1976;12(6):189–195. [PubMed] [Google Scholar]
  2. Degen P. H., Riess W. Simplified method for the determination of oxprenolol and other beta-receptor-blocking agents in biological fluids by gas-liquid chromatography. J Chromatogr. 1976 Jun 9;121(1):72–75. doi: 10.1016/s0021-9673(00)82299-2. [DOI] [PubMed] [Google Scholar]
  3. Ferlinz J., Easthope J. L., Hughes D., Siegel J., Tobis J., Aronow W. S. Antihypertensive and hemodynamic effects of oxprenolol versus propranolol. Clin Pharmacol Ther. 1980 Jun;27(6):733–743. doi: 10.1038/clpt.1980.104. [DOI] [PubMed] [Google Scholar]
  4. Kendall M. J., John V. A., Quarterman C. P., Welling P. G. A single and multiple dose pharmacokinetic and pharmacodynamic comparison of conventional and slow-release metroprolol. Eur J Clin Pharmacol. 1980 Feb;17(2):87–92. doi: 10.1007/BF00562615. [DOI] [PubMed] [Google Scholar]
  5. McAinsh J., Baber N. S., Smith R., Young J. Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol. 1978 Aug;6(2):115–121. doi: 10.1111/j.1365-2125.1978.tb00835.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McDevitt D. G., Brown H. C., Carruthers S. G., Shanks R. G. Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther. 1977 May;21(5):556–566. doi: 10.1002/cpt1977215556. [DOI] [PubMed] [Google Scholar]
  7. Meffin P. J., Winkle R. A., Peters F. A., Harrison D. C. Dose-dependent acebutolol disposition after oral administration. Clin Pharmacol Ther. 1978 Nov;24(5):542–547. doi: 10.1002/cpt1978245542. [DOI] [PubMed] [Google Scholar]
  8. Thadani U., Davidson C., Singleton W., Taylor S. H. Comparison of the immediate effects of five beta-adrenoreceptor-blocking drugs with different ancillary properties in angina pectoris. N Engl J Med. 1979 Apr 5;300(14):750–755. doi: 10.1056/NEJM197904053001402. [DOI] [PubMed] [Google Scholar]
  9. Theeuwes F., Swanson D. R., Guittard G., Ayer A., Khanna S. Osmotic delivery systems for the beta-adrenoceptor antagonists metoprolol and oxprenolol: design and evaluation of systems for once-daily administration. Br J Clin Pharmacol. 1985;19 (Suppl 2):69S–76S. doi: 10.1111/j.1365-2125.1985.tb02745.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. West M. J., Kendall M. J., Mitchard M., Faragher E. B. A comparison of slow release with conventional oxprenolol: plasma concentrations and clinical effects. Br J Clin Pharmacol. 1976 Jun;3(3):439–443. doi: 10.1111/j.1365-2125.1976.tb00619.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Wood A. J., Carr K., Vestal R. E., Belcher S., Wilkinson G. R., Shand D. G. Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol. 1978 Oct;6(4):345–350. doi: 10.1111/j.1365-2125.1978.tb00862.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Woods K. L., Linton S. P., Kendall M. J., Faragher E. B., Grieve R. J. Exercise responses of healthy subjects in the evaluation of cardioselectivity of beta-blockers. Eur J Clin Pharmacol. 1979 May 21;15(4):229–233. doi: 10.1007/BF00618510. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES